[{"address1": "4960 Peachtree Industrial Boulevard", "address2": "Suite 240", "city": "Norcross", "state": "GA", "zip": "30071", "country": "United States", "phone": "678 620 3186", "website": "https://galectintherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.", "fullTimeEmployees": 28, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joel  Lewis", "age": 53, "title": "President, CEO & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 907723, "exercisedValue": 0, "unexercisedValue": 19250}, {"maxAge": 1, "name": "Dr. Pol F. Boudes M.D., Ph.D.", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 730334, "exercisedValue": 0, "unexercisedValue": 13750}, {"maxAge": 1, "name": "Robert  Tritt", "title": "General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeff  Katstra", "title": "Head of CMC & Pharmaceutical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Beth  Knowles", "title": "Executive Assistant & Officer Manager", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.2, "open": 4.25, "dayLow": 3.75, "dayHigh": 4.2684, "regularMarketPreviousClose": 4.2, "regularMarketOpen": 4.25, "regularMarketDayLow": 3.75, "regularMarketDayHigh": 4.2684, "beta": 0.88, "forwardPE": -2.4968553, "volume": 491435, "regularMarketVolume": 491435, "averageVolume": 129714, "averageVolume10days": 418390, "averageDailyVolume10Day": 418390, "bid": 3.92, "ask": 4.01, "bidSize": 100, "askSize": 100, "marketCap": 245757696, "fiftyTwoWeekLow": 1.28, "fiftyTwoWeekHigh": 4.27, "fiftyDayAverage": 2.2512, "twoHundredDayAverage": 1.89815, "currency": "USD", "enterpriseValue": 294127584, "floatShares": 42694963, "sharesOutstanding": 61903700, "sharesShort": 2245477, "sharesShortPriorMonth": 2100200, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0363, "heldPercentInsiders": 0.31120002, "heldPercentInstitutions": 0.116739996, "shortRatio": 21.23, "shortPercentOfFloat": 0.0759, "impliedSharesOutstanding": 61903700, "bookValue": -1.01, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -37567000, "trailingEps": -0.74, "forwardEps": -1.59, "lastSplitFactor": "1:6", "lastSplitDate": 1332460800, "52WeekChange": 0.955665, "SandP52WeekChange": 0.23416412, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GALT", "underlyingSymbol": "GALT", "shortName": "Galectin Therapeutics Inc.", "longName": "Galectin Therapeutics Inc.", "firstTradeDateEpochUtc": 1031146200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "7b109f3e-2059-3335-8b86-82e0d6c5f2dc", "messageBoardId": "finmb_1065415", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.97, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 25660000, "totalCashPerShare": 0.415, "totalDebt": 71807000, "quickRatio": 1.637, "currentRatio": 1.768, "returnOnAssets": -0.96171, "freeCashflow": -20678000, "operatingCashflow": -32965000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-13"}]